-
link
GNTbm’s Trial on New Epigenetic Drug Generates Hope for Patients with Breast Cancer
GNTbm’s Trial on New Epigenetic Drug Generates Hope for Patients with Breast Cancer.
2021-07-23
-
link
GNTbm announces licensing of exclusive sales/marketing rights of anticancer drug Chidamide to Taiwan Specialty Pharma Corp. (TSPC)
GNT Biotech & Medicals Co., Ltd. (GNTbm, TPEx Emerging: 7427) announced that it has awarded exclusive sales and marketing rights in Taiwan of anticancer drug Chidamide to pharmaceutical distribution company Taiwan Specialty Pharma Corp. (TSPC)
2018-06-21
-
link
GNTbm to begin Phase III clinical trial in Taiwan of Chidamide for breast cancer
GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer
2017-04-19
-
link
GNTbm Exhibits at the 2016 BIO
GNTbm Exhibits at the 2016 BIO
2016-06-04
-
link
GNTbm Updates Developments in the Vaucarrin® Nanogold Drug Delivery Platform
GNTbm Updates Developments in the Vaucarrin® Nanogold Drug Delivery Platform
2015-09-01
-
link
GNT Biotech and Medicals Corporation Licenses Novel Cancer Molecule from Shenzhen Chipscreen Biosciences Ltd.
GNT Biotech and Medicals Corporation Licenses Novel Cancer Molecule from Shenzhen Chipscreen Biosciences Ltd.
2013-10-10
